PAPER Bosco D, Plastino M, Cristiano D, Colica C, Ermio C, De Bartolo M, Mungari P, Fonte G, Consoli D, Consoli A, Fava A
SEARCH RESULTS
330029 RESULTS
PAPER Chen PY, Tsai CT, Ou CY, Hsu WT, Jhuo MD, Wu CH, Shih TC, Cheng TH, Chung JG
Computational analysis of novel drugs designed for use as acetylcholinesterase inhibitors and histamine H3 receptor antagonists for Alzheimer's disease by docking, scoring and de novo evolution.
Mol Med Report. 2012 Apr;5(4):1043-8. PubMed: 22267207PAPER Wittnam JL, Portelius E, Zetterberg H, Gustavsson MK, Schilling S, Koch B, Demuth HU, Blennow K, Wirths O, Bayer TA
Pyroglutamate amyloid β (Aβ) aggravates behavioral deficits in transgenic amyloid mouse model for Alzheimer disease.
J Biol Chem. 2012 Mar 9;287(11):8154-62. PubMed: 22267726Richard Bedlack on Unusual ALS Case Highlights Variable Onset
COMMENT In my opinion the major message here is that there is a good deal of heterogeneity in all forms of ALS, even in specific subtypes of familial ALS such as this. This includes variability in penetrance, age and site of onset, comorbidities (for example deme
Richard Bedlack
Duke UniversityUnited States